P0723: Lengthening ustekinumab treatment intervals from every 8 to every 12 weeks in IBD patients in stable remission: preliminary results of a prospective observational cohort studyECCO'25Year: 2025
Authors: Devillers, M.(1)*;Fons, A.(2);West, R.(3);Van Der Marel, S.(4);Theeuwen, R.(2);Van Schaik, F.(5);Löwenberg, M.(6);Visschedijk, M.(7);Pierik, M.(8);Mujagic, Z.(8);Duijvestein, M.(9);Lauranne, D.(1);De Vries, A.(1);Van Der Meulen-de Jong, A.(2);
(1)Erasmus MC University Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(3)Franciscus Gasthuis & Vlietland, Gastroenterology and hepatology, Rotterdam, The Netherlands;(4)Haaglanden Medisch Centrum, Gastroenterology and hepatology, The Hague, The Netherlands;(5)University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(6)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(8)Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(9)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands; Initiative on Crohn’s and Colitis (ICC)
1.Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med 2016 Nov 17;375(20):1946-1960
2.Sands BE, Sandborn WJ, Pannaccione R, O’Brien CD, Zhang H, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019 Sept 26; 381(13):1201-1214
3.Bai Y, Sun Y, He Q, Bai X, Yang H. Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2024 Apr 1;36(4):359-370
4.Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G, et al. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis 2021 Nov 8;15(11):1920-1930.
P0724: Endoscopic and radiological outcomes of strictureplasty in patients with small bowel stricturing Crohn's diseaseECCO'25Year: 2025
Authors: Zhang, X.(1)*;Li, Y.(2);Zhu, W.(3);
(1)Jinling Hospital- Medical School of Southeast University, Department of General Surgery, Nanjing, China;(2)Jinling Hospital, Department of General Surgery, Nanjing, China;(3)Affiliated Hospital of Nanjing University of Chinese Medicine, Department of Colorectal and Proctology, Nanjing, China;
P0725: The fragility of randomized clinical trials in evaluating novel therapies for Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Chen, R.(1)*;Zheng, J.(1);Huang, P.(2);Li, L.(1);Chen, M.(1);Zhang, S.(1);
(1)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(2)Sun Yat-sen University, Zhongshan School of Medicine, Guangzhou, China;
1. Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 2014;67:622-8.
2. Caldwell JE, Youssefzadeh K, Limpisvasti O. A method for calculating the fragility index of continuous outcomes. J Clin Epidemiol 2021;136:20-25.
P0726: The Moderating Role of Adverse Childhood Experiences in the Relationship between Crohn's Disease Activity and the Development of PTSD SymptomsECCO'25Year: 2025
Authors: Di Vincenzo, F.(1)*;Spagnolo, G.(2);Vecchione, M.(3);D'Onofrio, A.M.(4);Camardese, G.(4);Sani, G.(4);Gasbarrini, A.(5);Cammarota, G.(6);Chieffo, D.P.R.(2);Ferrarese, D.(2);Scaldaferri, F.(7);
(1)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, Clinical Psychology Unit, Roma, Italy;(3)Sapienza University of Rome, Department of Social and Developmental Psychology, Roma, Italy;(4)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, Department of Neuroscience- Section of Psychiatry, Roma, Italy;(5)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, UOC Medicina Interna e Gastroenterologia- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Roma, Italy;(6)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, UOC Gastroenterologia - Dipartimento di Scienze Mediche e Chirurgiche, Roma, Italy;(7)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, IBD Unit- CeMAD Translational Research Laboratories- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;
P0728: Interventions for ocular extraintestinal manifestations in inflammatory bowel disease: an umbrella review of systematic reviewsECCO'25Year: 2025
Authors: Estevinho, M.M.(1)*;Solitano, V.(2);Magro, F.(3);Yuan, Y.(2);Jairath, V.(2);
(1)Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal;(2)Western University- London- Ontario, Gastroenterology, London, Canada;(3)Unidade Local de Saúde de São João, Gastroenterology, Porto, Portugal;
Licona Vera E, Betancur Vasquez C, Peinado Acevedo JS, Rivera Bustamante T, Martinez Redondo JM. Ocular Manifestations of Inflammatory Bowel Disease. Cureus. 2023;15(6):e40299
P0729: Comparative clinical outcomes of advanced therapy in bio-naïve versus bio-experienced patients hospitalized with Acute Severe Ulcerative Colitis: A retrospective cohort studyECCO'25Year: 2025
Authors: Hwang, S.W.(1,2)*;Kim, S.(1);Lee, C.H.(1);Kim, J.W.(1);Kim, M.K.(1);Lee, S.(1);Hong, S.W.(1);Park, S.H.(1,2);Yang, D.H.(1);Ye, B.D.(1,2);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,2);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology and Internal Medicine, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P0730: Inflammatory Bowel Disease Lifestyle Food and Exercise (IBDLiFE) study: a randomized controlled trial to investigate the effectiveness of a personalised diet and physical activity intervention for adults with inactive IBD in Aotearoa, New ZealandECCO'25Year: 2025
Authors: Yap, J.(1)*;Wall, C.L.(2);Meredith-Jones, K.(1);Iosua, E.(3);Osborne, H.(1);Michael, S.(1);
(1)University of Otago, Medicine, North Dunedin, New Zealand;(2)University of Otago, Medicine, Christchurch, New Zealand;(3)University of Otago, Biostatistics Centre, North Dunedin, New Zealand;
P0732: A cost comparison of treatment sequencing for Ulcerative Colitis: vedolizumab vs ustekinumab as a second-line biologic in anti-TNF-exposed patients in CanadaECCO'25Year: 2025
Authors: Martin, M.(1);Zhou, J.Y.(2)*;Mac, S.(2);Kao, K.E.(1);Johnston, K.(1);Marshall, J.K.(3);
(1)Broadstreet Health Economics and Outcomes Research, Broadstreet Health Economics and Outcomes Research, Vancouver, Canada;(2)Takeda Canada Inc., Patient Value and Access, Toronto, Canada;(3)McMaster University, Department of Medicine Division of Gastroenterology and Farncombe Family Digestive Health Research Institute-, Hamilton, Canada;
1. Wetwittayakhlang P, Lontai L, Gonczi L, et al. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med. 2021;10(23).
2. Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Therap Adv Gastroenterol. 2023;16:17562848231159452.
P0733: REALASA: Real-world effectiveness assessment of first-line 5-ASA for the treatment of Ulcerative Colitis in SwedenECCO'25Year: 2025
Authors: Christophersen, B.(1);Nielsen, L.(2);Landeira, M.(3);Guedes, S.(4)*;
(1)Ferring Pharmaceuticals Inc., Medical Affairs, Copenhagen, Denmark;(2)Ferring Pharmaceuticals Inc., Statistics, Copenhagen, Denmark;(3)Ferring Pharmaceuticals Inc., Health Economics and Outcomes Research, Copenhagen, Denmark;(4)Ferring Pharmaceuticals Inc., Real-world Evidence, Copenhagen, Denmark;
P0734: Real-World Experience of Curcumin+Qing Dai Reduces Biochemical and Intestinal Ultrasound Disease Markers in Patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Krugliak Cleveland, N.(1)*;Duty, C.(1);Bhondwe, K.(1);Rubin, D.(1);
(1)University of Chicago Medical Center, Inflammatory Bowel Disease Center, Chicago, United States;
1. Ben-Horin S, Salomon N, Karampekos G, et al. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2024;22(2):347-356.e6. doi:10.1016/j.cgh.2023.05.023
P0735: Early dietetic assessment predicts clinical efficacy of Exclusive Enteral Nutrition in adults with Crohn’s diseaseECCO'25Year: 2025
Authors: Chu, M.(1,2,3)*;Day, A.S.(1,3,4);Bogatic, D.(1,2,3);Hatzi, M.(4);Chu, S.K.(2);Costello, S.P.(1,2,3);Bryant, R.V.(1,2,3);
(1)The Queen Elizabeth Hospital, The Department of Gastroenterology and Hepatology, Adelaide, Australia;(2)University of Adelaide, School of Health and Medical Sciences, Adelaide, Australia;(3)Basil Hetzel Institute, Inflammatory Bowel Disease Research Group, Adelaide, Australia;(4)The Queen Elizabeth Hospital, Nutrition and Dietetics, Adelaide, Australia;
P0736: Analysis of endoscopic recurrence risk factors in Crohn's disease after surgical treatment within 1 yearECCO'25Year: 2025
Authors: Wei, T.(1);Guo, H.(1)*;Xiaomei, S.(1);Le, H.(1);
(1)Chongqing General Hospital, Gastroenterology, Chongqing, China;
1. Katz S. "Mind the gap": an unmet need for new therapy in IBD. J Clin Gastroenterol. 2007;41(9):799-809. doi:10.1097/ MCG.0b013e318033d71d
2. Kayal M, Posner H, Spencer E, Colombel JF, Stalgis C, Ungaro RC. Net remission rates with biologic and small molecule treatment in ulcerative colitis: a reappraisal of the clinical trial data. Clin Gastroenterol Hepatol. Published online January 12, 2023. doi:10.1016/j.cgh.2023.01.005
3. TASNEEM A, FLORIAN R, CLAUDIO F, et al. Pathogenesis of postoperative recurrence in Crohn's disease.[J]. Gut, 2011,60(4)
4. SOLBERG I C, CVANCAROVA M, VATN M H, et al. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn’s disease (the IBSEN Study)[J]. Inffamm Bowel Dis, 2014, 20(1): 60-68.
5. REGUEIRO M, KIP K E, BAIDOO L, et al. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence[J]. Clin Gastroenterol Hepatol, 2014, 12(9): 1494-1502.
6. Donnellan CF, Yann LH, Lal S. Nutritional management of Crohn’s disease. Therap Adv Gastroenterol. (2013) 6:231–42. doi: 10.1177/1756283X13477715
7. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. (2009) 15:2570–8. doi: 10.3748/wjg.15.2570
8. Van Assche G, Dignass A, Panes J, et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4(1):7-27
9.朱维铭，李 毅，余 超，等． 肠部分切除后吻合方式对克罗 恩病术后复发的影响． 中华胃肠外科杂志，2011，14( 3) : 168- 170．
10.Kullberg J, Brandberg J, Angelhed J E, et al. Whole-body adipose tissue analysis: Comparison of MRI, CT and dual energy X-ray absorptiometry[J]. Br J Radiol, 2009,82(974):123-130.
P0738: Apulian Network for Inflammatory Bowel Disease (AN-IBD) safety profile: Pilot dataECCO'25Year: 2025
Authors: Ditonno , I.(1);Contaldo , A.(1)*;Dell'Aquila , P.(1);Suriano , V.(1);Bossa , F.(2);Annese , M.(2);Perri , F.(2);Mazzuoli , S.(3);Guglielmi , F.W.(3);Bringiotti , R.(4);Palmisano , C.M.(5);Pranzo , G.(5);Albano , F.(6);Neve , V.(6);Tonti , P.(6);Stasi , E.(7);Facciorusso , A.(7);Marzo , M.(8);Paiano , P.(8);Gatti , F.(9);Di Lorenzo , M.P.(9);Fanigliulo , L.(10);Panarese , A.(10);Allegretta , L.(11);Bucci , A.(12);Hadad , Y.(13);Pisani , A.(14);Sacco , R.(15);Tursi , A.(16);Principi , M.(1);
(1)Policlinico di Bari- University of Bari "Aldo Moro", Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J- Gastroenterology Unit, Bari, Italy;(2)“Fondazione IRCCS - Casa Sollievo della Sofferenza”, Division of Gastroenterology, San Giovanni Rotondo, Italy;(3)"Monsignor Raffaele Dimiccoli" Hospital, IBD Unit- U.O.C. of Gastroenterology, Barletta, Italy;(4)“Di Venere” Hospital, Digestive Endoscopy Unit, Bari, Italy;(5)"Valle D'Itria" Hospital, Ambulatory for IBD Treatment, Martina Franca, Italy;(6)"A. Perrino" Hospital, Division of Gastroenterology, Brindisi, Italy;(7)"Vito Fazzi" Hospital, Department of Gastroenterology and Digestive Endoscopy, Lecce, Italy;(8)"Veris-Delli Ponti" Hospital, Division of Gastroenterology, Scorrano, Italy;(9)“F. Perinei” Hospital, Division of Gastroenterology, Altamura, Italy;(10)"S.S. Annunziata" Hospital, Division of Gastroenterology, Taranto, Italy;(11)"Santa Caterina Novella" Hospital, Division of Gastroenterology, Galatina, Italy;(12)“San Paolo” Hospital, Division of Gastroenterology, Bari, Italy;(13)“Card. Panico” Hospital, Division of Internal Medicine, Tricase, Italy;(14)National Institute of Gastroenterology IRCCS "Saverio de Bellis", Gastroenterology Unit, Castellana Grotte, Italy;(15)"Ospedali Riuniti", Gastroenterology Unit, Foggia, Italy;(16)Territorial Gastroenterology Service, Asl BAT, Andria, Italy;
P0739: Treatment persistence, clinical, and biological outcomes following an elective switch from intravenous to subcutaneous infliximab and vedolizumabECCO'25Year: 2025
Authors: Outtier, A.(1)*;Hoffert, Y.(2);De Dycker, E.(1);Geens, P.(1);Lambrechts, T.(1);Loddewijkx, E.(1);Paps, A.(1);Verstockt, B.(1);Sabino, J.(1);Vermeire, S.(1);Ferrante, M.(1);
(1)UZ Leuven, Gastroenterology, Leuven, Belgium;(2)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium; TARGID
P0740: Effectiveness and safety of ustekinumab in elderly Crohn's Disease patientsECCO'25Year: 2025
Authors: Ruiz Núñez , I.(1);Morera Sauca , L.(1);Madrigal Domínguez , R.E.(2);Barrio Andrés , J.(1)*;De Prado Santos , Á.(1);Mata Román , L.(3);Marinero Muñoz , M.Á.(1);García Alonso , J.(1);
(1)Río Hortega Universitary Hospital, Gastrointestinal, Valladolid, Spain;(2)Valladolid Clinic Universitary Hospital, Gastrointestinal, Valladolid, Spain;(3)Medina Del Campo Hospital, Gastrointestinal, Medina Del Campo, Spain;
P0741: Adherence to mesalazine suppositories maintenance treatment in patients with ulcerative proctitis: MESUPO multicenter prospective observational study from GETECCUECCO'25Year: 2025
Authors: Ferreiro Iglesias, R.(1)*;Nieto García, L.(1);de Castro, M.L.(2);Pérez Galindo, P.(3);Hernández Camba, A.(4);García, M.J.(5);Calvo Íñiguez, M.(6);Rodríguez-Lago, I.(7);Martí, E.(8);Iriarte, A.(9);Pallarés, H.(10);Dueñas Sadornil, C.(11);Zabalza San Martín, L.(12);Ramirez de la Piscina, P.(13);Rodríguez, L.(14);Bastón Rey, I.(1);Martínez Cadilla, J.(2);Álvarez Cancelo, A.(15);Porto Silva, S.(1);Zabana, Y.(16);Barreiro-de Acosta, M.(1);
(1)Hospital Clínico Universitario de Santiago de Compostela. Fundación Instituto de Investigación Sanitaria de Santiago de Compostela FIDIS, Gastroenterology, Santiago de Compostela, Spain;(2)Complexo Hospitalario Universitario de Vigo CHUVI Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS-UVIGO, Gastroenterology, Vigo, Spain;(3)Complejo Hospitalario Universitario de Pontevedra. Instituto de Investigación Sanitaria Galicia Sur, Gastroenterology, Pontevedra, Spain;(4)Complejo Hospitalario Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(5)Hospital Universitario Marqués de Valdecilla. Grupo de Investigación Sanitaria Valdecilla IDIVAL. Universidad de Cantabria., Gastroenterology and Hepatology, Santander, Spain;(6)Hospital Universitario San Pedro-Logroño, Gastroenterology, Logroño, Spain;(7)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute- Galdakao, Gastroenterology, Bilbao, Spain;(8)Hospital Universitario Lucus Augusti, Gastroenterology, Lugo, Spain;(9)Hospital Zumarraga- OSI Goierri-Alto Urola, Gastroenterology, Gipuzkoa, Spain;(10)Hospital Juan Ramón Jiménez, Gastroenterology, Huelva, Spain;(11)Hospital Universitario de Cáceres, Gastroenterology, Cáceres, Spain;(12)Hospital Universitario de Navarra. Instituto de Investigación de Navarra idiSNA, Gastroenterology, Navarra, Spain;(13)Hospital Universitario de Álava, Gastroenterology Department, Álava, Spain;(14)Hospital Universitario de Bellvitge, Gastroenterology, L’Hospitalet del Llobregat, Spain;(15)Hospital Universitario Marqués de Valdecilla. Grupo de Investigación Sanitaria Valdecilla IDIVAL, Gastroenterology and Hepatology, Santander, Spain;(16)CIBERhed. Hospital Universitari Mutua Terrassa. Universitat Autónoma de Barcelona, Gastroenterology, Terrassa, Spain; Young Group of GETECCU
P0742: Real-world efficacy and safety of Upadacitinib in IBD patients. Preliminary data from the Apulian Network for Inflammatory Bowel Disease (AN-IBD).ECCO'25Year: 2025
Authors: Bossa, F.(1);Principi, M.B.(2)*;Marzo, M.(3);Stasi, E.(4);Mazzuoli, S.(5);Pranzo, G.(6);Sacco, R.(7);Fanigliulo, L.(8);Neve, V.(9);Tursi, A.(10);Rizzi, M.(11);Bringiotti, R.(12);Bucci, A.(13);Allegretta, L.(14);Contaldo, A.(15);Mastronardi, M.(16);De Tullio, N.(17);Hadad, Y.(18);Annese, M.(19);Delll'Aquila , P.(2);Palmisano, C.M.(2);Paiano, P.(3);Facciorusso, A.(4);Rima, R.(4);Guglielmi, F.W.(20);Sgarro, C.(7);Perri, F.(19);
(1)IRCCS 'Casa Sollievo della Sofferenza' Hospital, Department of Gastroenterology and Digestive Endoscopy, San Giovanni Rotondo, Italy;(2)Gastroenterology Unit- Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J- University of Bari, Gastroenterology, Bari, Italy;(3)UOC Gastroenterologia - Ospedale Veris Delli Ponti, Gastroenterology, Scorrano, Italy;(4)Gastroenterologia ed Endoscopia Digestiva Ospedale Vito Fazzi, Gastroenterology, Lecce, Italy;(5)Ospedale Di Miccoli- UOC Gastroenterologia, Gastroenterology, Barletta, Italy;(6)Digestive Endoscopy Unit- Martina Franca Hospital, Surgery, Martina Franca, Italy;(7)Gastroenterology and Digestive Endoscopy Unit- Foggia University Hospital, Gastroenterology, Foggia, Italy;(8)Division of Gastroenterology- "S.S. Annunziata" Hospital, Gastroenterology, Taranto, Italy;(9)Division of Gastroenterology, Gastroenterology, Brindisi, Italy;(10)Servizio di Gastroenterologia Territoriale- DSS n°4 di Barletta- ASL BAT, Gastroenterology, Andria, Italy;(11)UOSD Endoscopia Digestiva-Ospedale della Murgia "Fabio Perinei, Gastroenterology, Altamura, Italy;(12)UO di Endoscopia Digestiva – Ospedale di Venere, Gastroenterology, Bari, Italy;(13)UOC di Gastroenterologia ed Endoscopia Digestiva, Gastroenterology, Bari, Italy;(14)UOC di Gastroenterologia ed Endoscopia Digestiva – Ospedale Santa Caterina Novella, Gastroenterology, Galatina, Italy;(15)UOC di Gastroenterologia ed Endoscopia Digestiva – IRCCS Saverio De Bellis, Gastroenterology, Castellana Grotte, Italy;(16)UOSD IBD – IRCCS Saverio De Bellis, Gastroenterology, Castellana Grotte, Italy;(17)UOC di Gastroenterologia ed Endoscopia Digestiva – Ospedale Miulli, Gastroenterology, Acquaviva delle Fonti, Italy;(18)UOC di Medicina Interna – Ospedale Cardinale Giovanni Panico, Internal Medicin, Tricase, Italy;(19)UOC di Gastroenterologia ed Endoscopia Digestiva – Fondazione Casa Sollievo della Sofferenza – IRCCS, Gastroenterology, San Giovanni Rotondo, Italy;(20)Ospedale Di Miccoli- UOC Gastroenterologia- Barletta, Gastroenterology, Barletta, Italy;
P0743: Clinical impact of delayed access to advanced IBD treatment in Latin America. Experience of 8 years from a medium-volume center in Cordoba, Argentina.ECCO'25Year: 2025
Authors: Martín, S.(1);Rosario, T.(1);Balderramo, D.C.(2)*;
(1)Hospital Privado Universitario de Córdoba, Gastroenterology, Cordoba, Argentina;(2)Hospital Privado Universitario de Cordoba, IBD Section. Gastroenterology, Cordoba, Argentina;
Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, Ng SC, Kaplan GG, Kotze PG. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):263-272. doi: 10.1016/S2468-1253(23)00284-4. PMID: 38340754.
